Amarin shares sink on doubts about wider use of key drug

(Reuters) - Amarin Corp Plc's shares slumped as much as 64 percent on Thursday, a day after an advisory committee to the U.S. Food and Drug Administration voted against allowing the company's triglyceride-lowering drug for use in a broader patient population. The advisory committee recommended that the drug's approval be kept pending until the results of an 8,000-patient trial indicate whether the drug, Vascepa, actually does reduce cardiovascular risk. Results of the trial are not expected until 2016. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/amarin-shares-sink-doubts-wider-key-drug-175521959--finance.html